Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Gains from Investment Securities for 6 consecutive years, with $27.2 million as the latest value for Q3 2025.

  • Quarterly Gains from Investment Securities rose 8738.43% to $27.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Sep 2025, up 8738.43% year-over-year, with the annual reading at $17.2 million for FY2024, 2051.67% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $27.2 million at Inhibikase Therapeutics, up from $25.8 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $27.2 million in Q3 2025, with the low at $18039.0 in Q1 2024.
  • Average Gains from Investment Securities over 5 years is $5.5 million, with a median of $181762.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities plummeted 85.85% in 2021, then surged 118139.34% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $29839.0 in 2021, then soared by 156.88% to $76651.0 in 2022, then soared by 944.07% to $800293.0 in 2023, then surged by 2051.67% to $17.2 million in 2024, then skyrocketed by 58.11% to $27.2 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $27.2 million, $25.8 million, and $21.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.